Evidence map›Paper›PMID 32214787›Full record

ArticleMolecular vision2020

Exome sequencing identifies

Gema García-García, Iker Sanchez-Navarro, Elena Aller, Teresa Jaijo, Carla Fuster-Garcia, Ana Rodríguez-Munoz, Elena Vallejo, Juan José Tellería, Selma Vázquez, Sergi Beltrán and 9 more

Open access · greenAbstract readCase Reports
In one paragraph

Article in Molecular vision, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 2 countries.

Gema García-GarcíaResearch group on Molecular, Cellular and Genomic Biomedicine, Health Research, Institute La Fe (IIS La Fe) and Mixed Unit for Rare diseases IIS La Fe - CIPF, Valencia, Spain.
Iker Sanchez-NavarroCentre for Biomedical Research on Rare Diseases (CIBERER), Madrid, Spain.
Elena AllerResearch group on Molecular, Cellular and Genomic Biomedicine, Health Research, Institute La Fe (IIS La Fe) and Mixed Unit for Rare diseases IIS La Fe - CIPF, Valencia, Spain.
Teresa JaijoResearch group on Molecular, Cellular and Genomic Biomedicine, Health Research, Institute La Fe (IIS La Fe) and Mixed Unit for Rare diseases IIS La Fe - CIPF, Valencia, Spain.
Carla Fuster-GarciaResearch group on Molecular, Cellular and Genomic Biomedicine, Health Research, Institute La Fe (IIS La Fe) and Mixed Unit for Rare diseases IIS La Fe - CIPF, Valencia, Spain.
Ana Rodríguez-MunozResearch group on Molecular, Cellular and Genomic Biomedicine, Health Research, Institute La Fe (IIS La Fe) and Mixed Unit for Rare diseases IIS La Fe - CIPF, Valencia, Spain.
Elena VallejoDepartment of Ophthalmology, Medina del Campo Hospital, Valladolid, Spain.
Juan José TelleríaIBGM, University of Valladolid, Valladolid, Spain.
Selma VázquezUniversity Hospital of Valladolid, Valladolid, Spain.
Sergi BeltránNational Center of Genomic Analysis (CNAG-CRG) Centre for Genomic Regulation, Barcelona, Spain.
Sophia DerdakNational Center of Genomic Analysis (CNAG-CRG) Centre for Genomic Regulation, Barcelona, Spain.
Olga ZuritaCentre for Biomedical Research on Rare Diseases (CIBERER), Madrid, Spain.
Cristina Villaverde-MonteroCentre for Biomedical Research on Rare Diseases (CIBERER), Madrid, Spain.
Almudena Avila-FernándezCentre for Biomedical Research on Rare Diseases (CIBERER), Madrid, Spain.
Marta CortonCentre for Biomedical Research on Rare Diseases (CIBERER), Madrid, Spain.
Fiona Blanco-KellyCentre for Biomedical Research on Rare Diseases (CIBERER), Madrid, Spain.
Hakon HakonarsonThe Center for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, PA.
José M MillánResearch group on Molecular, Cellular and Genomic Biomedicine, Health Research, Institute La Fe (IIS La Fe) and Mixed Unit for Rare diseases IIS La Fe - CIPF, Valencia, Spain.
Carmen AyusoCentre for Biomedical Research on Rare Diseases (CIBERER), Madrid, Spain.
Centre for Biomedical Network Research on Rare Diseases · ESHospital Universitario Fundación Jiménez Díaz · ESUniversidad Autónoma de Madrid · ESUniversidad de Valladolid · ESHospital Universitari i Politècnic La Fe · ESUniversity of Pennsylvania · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The aim of the present work is the molecular diagnosis of three patients with deafness and retinal degeneration. Methods: Three patients from two unrelated families were initially analyzed with custom gene panels for Usher genes, non-syndromic hearing loss, or inherited syndromic retinopathies and further investigated by means of clinical or whole exome sequencing. Results: The study allowed us to detect likely pathogenic variants in Conclusions: We have reported three new cases with pathogenic variants in

Indexed as

AdultATPases Associated with Diverse Cellular ActivitiesChildCraniofacial AbnormalitiesDental EnamelExome SequencingFemaleHearing Loss, SensorineuralHumansIntellectual DisabilityMaleMutationNephrolithiasisNeurodevelopmental DisordersPedigreePeroxisomesATPases Associated with Diverse Cellular ActivitiesPEX6 protein, human

Identifiers

PMID32214787
PMCPMC7090270
OpenAlexW3013899512

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.